Among them, EGFR mutations can inhibit tumor immune response through various mechanisms, such as reducing the number and function of antigen-presenting cells, decreasing T-cell infiltration and activation, and increasing the number of immunosuppressive cells (26). Here, EGFR is linked to neoplasm.